1887

n Southern African Journal of HIV Medicine - Abacavir in children : Abacavir

USD

 

Abstract

Abacavir (ABC) (Ziagen) is a new nucleoside analogue reverse transcriptase inhibitor (NRTI). It has already been registered with the Medicines Control Council and should be launched some time in 2003. At present it is available on a named-patient basis from GlaxoSmith Kline. In contrast with the other NRTls, ABC is a quanosine antagonist.


Although the data on ABC in children are limited, there are a number of features of ABC that make it a useful drug in the antiretroviral arsenal. Conversely, as with all medications, there are some negative features that must be taken into account.

Loading

Article metrics loading...

/content/m_sajhiv/3/3/EJC65712
2002-01-01
2016-12-08
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error